XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3
GOODWILL AND OTHER INTANGIBLE ASSETS
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill

The changes in the carrying amounts in Goodwill were as follows:
Dollars in millions
Balance at December 31, 2023$21,169 
Acquisitions (Note 4)
580 
Currency translation and other adjustments2 
Balance at September 30, 2024
$21,751 

Other Intangible Assets

Other intangible assets consisted of the following:

Estimated
Useful Lives		September 30, 2024December 31, 2023
Dollars in millions
Gross carrying amountsAccumulated amortizationOther intangible assets, net Gross carrying amountsAccumulated amortizationOther intangible assets, net
R&D technology(a)
6 years
$1,980 $(193)$1,787 $— $— $— 
Acquired marketed product rights(a)
3 – 15 years
63,435 (47,048)16,387 63,076 (40,184)22,892 
Capitalized software
3 – 10 years
1,529 (1,114)415 1,497 (1,027)470 
IPRD(a)
8,375 — 8,375 3,710 — 3,710 
Total$75,319 $(48,355)$26,964 $68,283 $(41,211)$27,072 
(a)    Includes assets acquired in connection with Mirati and RayzeBio acquisitions, as further described in "—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements."

Amortization expense of Other intangible assets was $2.4 billion and $7.3 billion during the three and nine months ended September 30, 2024 and $2.3 billion and $6.9 billion during the three and nine months ended September 30, 2023, respectively.
The other intangible assets impairments were as follows (dollars in millions):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Cost of goods sold
$— $60 $280 (a)$80 
Research and development
— — 590 (b)— 
Other income/(expense)
47 29 47 29 
Total
$47 $89 $917 $109 
(a) Impairment relates to Inrebic, which resulted from lower revised cash flow projections. The charge represented a partial impairment based on the asset's carrying value over its estimated fair value using discounted cash flow projections.
(b) Impairment relates to alnuctamab, which resulted from portfolio prioritization. The charge represented a full write-down of the asset.